Ocean Biomedical, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Inderjote Kathuria
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Room 325, 55 Claverick Street Providence RI United States of America 02903
- IPO Date
- Nov 8, 2021
- CIK
- 0001869974
- Website
- oceanbiomedical.com
- Similar Companies
- Business
- Ocean Biomedical, Inc. (NASDAQ:OCEA) is a biopharmaceutical company focused on discovering and developing novel therapeutic products targeting oncology, fibrosis, and infectious diseases primarily in the United States. The company's core pipeline includes oncology candidates such as OCX-253, an anti-Chi3l1 single-target monoclonal antibody, and OCX-410, an anti-Chi3l1/PD-1 bi-specific antibody, both for non-small cell lung cancer; OCX-909, an anti-Chi3l1/CTLA-4 bi-specific antibody for glioblastoma multiforme; a small molecule targeting Chit1 for idiopathic pulmonary fibrosis and Hermansky-Pudlak syndrome in its fibrosis program; and infectious disease candidates comprising therapeutic and vaccine programs against malaria based on PfSEA-1 and PfGARP antigens. Founded in 2019 by Dr. Chirinjeev Kathuria and Dr. Jack A. Elias as a Brown University spin-off, Ocean Biomedical maintains headquarters in Providence, Rhode Island, and collaborates with leading global research institutions to advance preclinical programs toward clinical trials. Recent developments include a October 2024 strategic investment securing a 22% ownership stake in Virion Therapeutics for $9 million in cash and equity to expand its pharmaceutical influence; an exclusive licensing agreement with Poland-based Molecure (WSE:MOC) for the selective YKL-40 inhibitor program, including lead molecule OAT-3912; February 2025 publication of breakthrough findings on its EGFR-mutated cancer immunotherapy candidates; and an April 2025 expansion into energy and digital asset sectors to generate stable cash flow supporting its biopharma operations.
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
3 Trending Biotech Penny Stocks
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
Should You Sell Your Penny Stocks? 3 Tips for When to Sell
Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics
Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection